Evidence map›Paper›PMID 41413682›Full record

ArticleJournal of computer-aided molecular design2025

In silico-driven protocol for hit-to-lead optimization: a case study on PDE9A inhibitors.

Hiroyuki Ogawa, Masateru Ohta, Mitsunori Ikeguchi

Abstract read
In one paragraph

Article in Journal of computer-aided molecular design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hiroyuki OgawaGraduate School of Medical Life Science, Yokohama City University, 1-7-29 Suehiro-cho, Tsurumi-ku, Yokohama, 230-0045, Japan.ORCID http://orcid.org/0009-0000-8898-9316
Masateru OhtaHPC- and AI-driven Drug Development Platform Division, Center for Computational Science, RIKEN 1-7-22, Suehiro-cho, Tsurumi-ku, Yokohama, 230-0045, Japan.ORCID http://orcid.org/0000-0002-6580-7185
Mitsunori IkeguchiGraduate School of Medical Life Science, Yokohama City University, 1-7-29 Suehiro-cho, Tsurumi-ku, Yokohama, 230-0045, Japan. ike@yokohama-cu.ac.jp.ORCID http://orcid.org/0000-0003-3199-6931

Funding

Japan Agency for Medical Research and Development JP25ama121023Japan Agency for Medical Research and Development JP25fk0310525
6 · The paper itself

Abstract

Hit-to-lead (H2L) optimization is a critical stage in small-molecule drug discovery, where efficient exploration of chemical space is required to identify promising lead compounds. Conventional H2L workflows rely on iterative synthesis and experimental evaluation, which limit the range of chemical space that can be explored. In contrast, in silico approaches enable efficient selection of promising compounds from a much larger chemical space by generating large numbers of virtual compounds and evaluating them computationally. To harness this potential, we developed an in silico-driven H2L protocol that integrates molecular generation, binding affinity prediction based on relative binding free energies calculated using the non-equilibrium switching (NES) method, and the evaluation of key properties-such as solubility, metabolic stability, and membrane permeability-using machine learning (ML) techniques. In this study, within the context of H2L optimization, we examined the applicability, accuracy, and utility of NES, a relatively new high-precision binding free energy calculation method, and evaluated its effectiveness in large-scale exploration of substituent space. The phosphodiesterase 9A inhibitor was used as a model system. Starting from the reported high-throughput screening hit compound, we first modified the core structure and then sequentially conducted large-scale exploration of two substitution sites. Following this protocol, we narrowed down compounds predicted to those exhibiting not only high binding affinity but also favorable physicochemical and ADME-related properties. Among these, we verified whether the lead compound reported in the literature was included, and confirmed that it appeared as one of the top-ranked candidates. These results demonstrate that an in silico protocol combining large-scale molecular generation, high-accuracy affinity prediction using NES, and ML-based ADME prediction enables H2L optimization that considers a broader substituent space.

Indexed as

3',5'-Cyclic-AMP PhosphodiesterasesDrug DiscoveryPhosphodiesterase InhibitorsComputer SimulationDrug DesignHumansMachine LearningMolecular Docking SimulationProtein BindingSmall Molecule LibrariesStructure-Activity RelationshipThermodynamics3',5'-Cyclic-AMP PhosphodiesterasesPDE9A protein, humanPhosphodiesterase InhibitorsSmall Molecule LibrariesDrug discoveryHit-to-leadNon-equilibrium switchingPDE9A

Identifiers

PMID41413682
PMCPMC12715073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.